BFM
CYCN icon

Boothbay Fund Management’s Cyclerion Therapeutics CYCN Stock Holding History

Boothbay Fund Management’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,538
Closed -$56K – 2328
2022
Q1 		$56K Hold
2,538
– – ﹤0.01% 2165
2021
Q4 		$87K Hold
2,538
– – ﹤0.01% 1731
2021
Q3 		$156K Sell
2,538
-811
-24% -$53.1K ﹤0.01% 1654
2021
Q2 		$261K Buy
3,349
+1,643
+96% +$103K 0.01% 1368
2021
Q1 		$95K Buy
+1,706
New +$128K ﹤0.01% 1477

Other funds holding CYCN

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TFS
TrustCore Financial Services Brentwood, Tennessee $1.14B AUM 13.32% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $385M AUM 31.69% 1-Year Est. Return

Boothbay Fund Management's CYCN Position: Q2 2022 in Review

Boothbay Fund Management sold out of Cyclerion Therapeutics (CYCN) in Q2 2022, closing a stake of 2,538 shares — an estimated $56K sold.

Boothbay Fund Management first reported a position in CYCN in Q1 2021 and held it in 5 quarters. The position peaked at $261K in Q2 2021. 41 funds tracked by Wall St. Rank hold CYCN as of Q2 2022.

  • Boothbay Fund Management reported no remaining Cyclerion Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Boothbay Fund Management sold 2,538 Cyclerion Therapeutics shares in Q2 2022, an estimated $56K.
  • Boothbay Fund Management first reported a position in Cyclerion Therapeutics in Q1 2021 and held it in 5 quarters.
  • Boothbay Fund Management's Cyclerion Therapeutics position peaked at $261K in Q2 2021.
  • 41 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q2 2022.

Based on Boothbay Fund Management's 13F filing for Q2 2022, filed 15 Aug 2022.